REDUCED BIOAVAILABILITY OF MOISTURE-EXPOSED CARBAMAZEPINE RESULTING IN STATUS EPILEPTICUS

被引:14
作者
BELL, WL
CRAWFORD, IL
SHIU, GK
机构
[1] UNIV TEXAS,SW MED CTR,DEPT NEUROL,DALLAS,TX
[2] US FDA,BIOPHARMACEUT RES BRANCH,WASHINGTON,DC 20204
关键词
CARBAMAZEPINE; BIOAVAILABILITY; STATUS EPILEPTICUS; HUMIDITY; DRUG TOXICITY;
D O I
10.1111/j.1528-1157.1993.tb02140.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A 28-year-old man with seizures well controlled with carbamazepine (CBZ) and valproate (VPA) developed generalized convulsive status epilepticus three days after his CBZ tablets became wet during a rainstorm while he was camping out. He continued the CBZ but avoided ingesting obviously disintegrating tablets. The VPA was not exposed to excessive moisture. Previous random CBZ blood levels had been in the range of 9-13 mu g/ml; at the time of admission to the emergency room the level had decreased to 3.8 mu g/ml. The VPA level did not change significantly from baseline. The moisture-exposed CBZ tablets were of expected weight but were swollen and enlarged. Analysis of these tablets by USP paddle method 2 demonstrated a mean dissolution of 16% at 60 min as compared with >80% for fresh CBZ tablets. After final dissolution of the moisture-exposed CBZ tablets, normal quantities of active drug were noted. We propose that poor dissolution of moisture-exposed CBZ tablets results in reduced bioavailability. We urge caution in the packaging and storage of CBZ to avoid exposure to moisture.
引用
收藏
页码:1102 / 1104
页数:3
相关论文
共 9 条
[1]   CLINICAL PHARMACOKINETICS AND PHARMACOLOGICAL EFFECTS OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE - AN UPDATE [J].
BERTILSSON, L ;
TOMSON, T .
CLINICAL PHARMACOKINETICS, 1986, 11 (03) :177-198
[2]   REDUCED SEIZURE CONTROL DUE TO SPOILED PHENYTOIN CAPSULES [J].
CLOYD, JC ;
GUMNIT, RJ ;
LESAR, TS .
ANNALS OF NEUROLOGY, 1980, 7 (02) :191-193
[3]   INVITRO AND INVIVO EVALUATION OF 7 50 MG AND 100 MG NITROFURANTOIN TABLETS [J].
MEYER, MC ;
WOOD, GC ;
STRAUGHN, AB .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1989, 10 (03) :321-329
[4]   INVITRO DISSOLUTION PROFILE OF WATER-INSOLUBLE DRUG-DOSAGE FORMS IN THE PRESENCE OF SURFACTANTS [J].
SHAH, VP ;
KONECNY, JJ ;
EVERETT, RL ;
MCCULLOUGH, B ;
NOORIZADEH, AC ;
SKELLY, JP .
PHARMACEUTICAL RESEARCH, 1989, 6 (07) :612-618
[5]   BIOAVAILABILITY AND BIOEQUIVALENCE [J].
SKELLY, JP .
JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 16 (10) :539-545
[6]  
WANG JT, 1990, PHARMACOL RES S, V9, pS143
[7]  
1990, US PHARMACOPEIA, P222
[8]  
1990, FDA DRUG B, V20, P5
[9]  
1990, FDA CONSUM, V24, P3